Navigation Links
SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

SAN DIEGO, March 4 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) will announce financial results for the fourth quarter and full year 2007 on Wednesday, March 12, 2008. The announcement will be followed by a live conference call and webcast at 8:00 a.m. Pacific Time. Mike Grey, President and Chief Executive Officer, and Todd Myers, Chief Financial Officer, will host the conference call to discuss financial results and business highlights.

Interested participants and investors may access the teleconference call by dialing 800-573-4752 (U.S./Canada) or 617-224-4324 (international), participant code 20358556. A telephonic replay will be available for seven days following the call. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international), participant code 55640708.

A live webcast will be available under the investor relations section of the Company's website at http://www.sgxpharma.com. Replays of the webcast will be available for 30 days following the event. Please connect to the Company's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as SGX523, a cMET kinase inhibitor currently in Phase 1 clinical studies, next generation BCR-ABL inhibitors being developed by SGX and in collaboration with Novartis, and JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE SGX Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
2. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
7. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
11. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... NASHVILLE, Tenn. , April 27, 2017  Pendant ... company developing innovative surface modification and drug delivery technologies, ... & Johnson Innovation, JLABS @ Toronto ... Chief Executive Officer of Pendant Biosciences, noted, "We are ... Toronto community, and are honored to ...
(Date:4/26/2017)... ... ... LABS, Inc. (LABS) announced in December 2016 that two new Zika ... Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for IgM and IgG ZIKV ... donors under an Investigational New Drug (IND) study protocol. , Now, as part ...
(Date:4/25/2017)... ... April 25, 2017 , ... As part of the Stago ... the laboratory testing for DIC in order to illuminate this clinical problem for people ... in hospitalized patients resulting in a high degree of morbidity and mortality. DIC is ...
(Date:4/25/2017)... ... April 25, 2017 , ... Covalent Metrology ... Analytical Services unit provides high-quality data to clients, both faster and cheaper ... receipt. There are no price premiums, and customers are welcome to participate in ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
Breaking Biology News(10 mins):